Media

60° Pharmaceuticals (60P) Media center

Here you’ll find relevant information about our company, including press, and events focusing on the development of tropical disease medicines for malaria prevention and dengue fever treatment.

Events

ON-DEMAND WEBINAR: Plans for Further Development of ARAKODA® (tafenoquine)

Please join CEO Geoffrey Dow as he discusses future plans for testing of ARAKODA® (tafenoquine) for potential use in COVID-19 in light of recent in vitro study results.

WATCH NOW

 

View Archive

Press

July 14, 2020

60 Degrees Pharmaceuticals Announces Positive Results of Cell Culture Testing of ARAKODA® (tafenoquine) for COVID-19

READ MORE

 

November 21, 2019

Arakoda™ (tafenoquine) tablets, first prescription drug approved for malaria prevention by US FDA in over 18 years,

now available in US

READ MORE

 

March 20, 2019

60 Degrees Pharmaceuticals (60P) achieves first global product launch milestone
READ MORE

 

September 18, 2018

KODATEF® (tafenoquine) approved in Australia; first malaria prevention drug in more than two decades
READ MORE

 

August 27, 2018

Military scientists have discovered a new malaria drug that could help eradicate the disease — and it’s hitting shelves soon
READ MORE

 

August 9, 2018

US Food and Drug Administration Approves ARAKODA™ (tafenoquine) tablets for oral use
READ MORE

 

July 26, 2018

USFDA Advisory Committee votes in favor of Tafenoquine for the prevention of malaria
READ MORE

 

View Archive

60P Media Relations:

Lois Kaufman

lkaufman@imsworld.com

Phone: +1 609.683.9055  x203

405,000

Annual deaths from malaria globally

125,000,000

Travelers to endemic regions per annum

390,000,000

Dengue infections per year

202-327-5422

1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036